Global HELLP Syndrome Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|全球HELLP症候群市場(2020年∼2027年) Global HELLP Syndrome Market - 2020-2027|
|出版日期: 2021年05月04日||內容資訊: 英文 180 Pages||
妊娠相關並發症發生率的增加，加上診斷試劑盒的最新發展，預計將推動市場增長。此外，患者和醫療保健提供者對包括妊娠毒血症在內的健康狀況嚴重性的認識不斷提高，將進一步提高全球對 HELLP 綜合徵的需求。以合理的價格輕鬆獲得有效資源，例如妊娠毒血症試劑和其他產品，預計將在預測期內推動 HELLP 綜合徵市場的滲透。
HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome is a rare life-threatening disorder commonly related to preeclampsia and eclampsia. It further causes issues with the liver, bleeding, and blood pressure. It is widely used in the healthcare sector to diagnose blood pressure measurement, red blood cell count, blood tests for an enzyme that reveal cell damage, urine test for protein, and more. Blood testing and urine analysis are the standard tests used to diagnosis the condition of HELLP syndrome. The condition usually affects the female population during pregnancies and may significantly after the infant is delivered. Perhaps, it often the greater risk of complication from premature delivery of babies when the women develop HELLP syndrome. As such, the need for HELLP syndrome treatment is gaining significant momentum in recent years to mitigate such risks associated with the disorder.
The global HELLP syndrome market size was worth US$ XX billion in 2020 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).
The growth in incidence of pregnancy-associated complications coupled with the recent developments in diagnostics kits is expected to propel the market growth. Furthermore, the rising awareness among patients and healthcare providers for the severity of health conditions, including preeclampsia, will further enhance the HELLP syndrome demand globally. The easy accessibility of effective resources at a reasonable price, such as preeclampsia reagents and other products, is expected to fuel the penetration of the HELLP syndrome market during the forecast period.
Rising incidences of pre-eclampsia around the world
In the recent market scenario, pre-eclampsia is a staple to develop HELLP syndromes in many women worldwide, which is strengthening the demand for HELLP syndrome treatment, as it may create blood clotting problems and placenta & liver problems among women and infant during pregnancies. Along with this, the rising perinatal and maternal morbidity & mortality rate is setting to promote the need for the early diagnosis of pre-eclampsia among pregnant women globally. Moreover, the prevalence of pre-eclampsia, a precursor to eclampsia, differs greatly around the world. According to the World Health Organization (WHO) predicts that the incidence of pre-eclampsia is to be seven times higher in emerging countries (almost 2.8% of live births) than occurred in developed countries (roughly 0.4%). Similarly, according to the American Heart Association, pre-eclampsia affects between 5% to 7% of all pregnant women; however, it is liable for more than 70,000 maternal deaths and 500,000 fetal deaths worldwide each year. Therefore, the rising cases of preeclmapsia among pregnant women globally and increasing the cases of infant mortalities due to developed HELLP syndrome in mothers enhances the utility for HELLP syndrome. Furthermore, a blood test is becoming more popular than a urine test, with advancements in the product technology for diagnosing pre-eclampsia has also been a significant factor for boosting the need for HELLP syndrome treatment in the global market throughout the forecast period.
Rapid growth in pregnancy products consumption in the Asia Pacific
As per the recent demographic condition, the growth in consumption of pregnancy products based on the development of HELLP syndrome among mothers is rapidly increasing in the Asia Pacific region, owing to an increase in the purchasing power and growing prevalence of pregnancy complications among the population. The demand is also enhanced due to its enhanced utilization in HELLP syndrome treatment to meet the unmet medical needs among women and further replace traditional medication solutions.
In addition, widening HELLP syndrome market opportunities is primarily due to the surging pregnancies in Asian countries are further reinforced the product demand in the Asia-Pacific region. Healthcare sector growth in the Asian economy is feasible due to improving healthcare infrastructure, increased hospital and diagnostic centre projects, and rising target populations. Supplementary driving factors to industry growth include changing women preferences towards hygienic products to mitigate the risk of pregnancy-based health complication, which further promoting the consumption of pregnancy products, which, in turn, driving the market growth during the forecast period.
COVID-19 Impact Analysis
COVID-19 pandemic has affected the global economy in several terms, such as directly impacting the production and demand, supply chain disruption, and financial impact. With the COVID-19 disruptions in various sectors, the manufacturers' supply chain in the healthcare sector has significantly improved on a global scale to control the spread of novel coronavirus diseases. However, the ongoing pandemic further resulted in shutting down the production facilities to minimize the risk of virus spread. Also, the lockdown policies have strengthened the demand for home setting healthcare products throughout the world to meet high unmet medical needs among patients, particularly pregnant women. Therefore, the manufacturers are keen to invest and expand their production capabilities to meet the global market's updated demand. Despite the pandemic, there is growth in the overall healthcare products, which is expected to drive the HELLP syndrome's market size in the global market during the forecast period.
Based on the product type, the HELLP syndrome market has been classified into isntument and consumable
Consumables segment accounted for the highest market share in the global market
In 2019, the consumable products segment was anticipated to account for the largest share, owing to the rise in availability of reagents and kits by numerous market players, along with better treatment outcomes. Such products often help treat HELLP syndromes, as they are efficient for the rapid detection of biomarkers indicating preeclampsia. Moreover, the increasing number of pregnancy complications due to growing pregnancies in developed and developing economies is paving the growth of the consumables segment in the global HELLP syndrome market during the forecast period.
Moreover, the instruments are highly fragile and deliver fast screening tests for the biochemical markers for the treatment of HELLP syndrome. These inherent traits possessed by the instruments may result in the creation of significant growth prospect for the HELLP syndrome-based instruments market.
Based on the application, the HELLP syndrome market has been classified into hospitals, specialty clinics, diagnostic centers, and others.
Diagnostic Centers segment dominated the global HELLP syndrome market in 2019
In 2019, the diagnostic centers segment dominated the HELLP syndrome market, owing to the rising presence of advanced diagnostic instruments at these centers, and thus is the viable and efficient choice for the HELLP syndrome diagnosis. It is also expected that the diagnostic centers application is expected to grow with a significant CAGR during the forecast period, owing to they provide precise detection of HELLP syndrome development at the initial stage.
The hospital segment is expected to account for the second-largest market share, followed by specialty clinics. The hospital segment is predicted to register the second-highest CAGR throughout the forecast period, owing to its increasing rate of hospitalization coupled with growing funding and investments in hospital infrastructure projects. For instance, as per the Agency for Healthcare Research and Quality (AHRQ), around 176,925 cases of deliveries performed at hospitalization settings in 2017 across the U.S. Therefore, it is estimated to be a potential in the hospital-based diagnosis of HELLP Syndrome market.
Based on geography, the study analyzes the HELLP syndrome market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America leads the global market throughout the forecast period.
North America dominates the global HELLP syndrome market in terms of value and volume due to the presence of leading manufacturing companies and easy accessibility of high-quality HELLP syndrome treatment products for healthcare facilities. It is also leading due to the growing complications in pregnancies or childbirth in the United States and other countries. While in Europe, the rising concern and high awareness for health-conscious disorders, along with the significant number of pregnancy failure case, will further enhance its market position in the global HELLP syndrome market in the coming years.
The Asia Pacific is estimated to grow at the HELLP syndrome market's highest growth rate during the forecast period. The growth of the region is attributing to the increasing number of pregnancy-related disorder on account of the growing female population coupled with improving healthcare infrastructure and facilities in the region. Also, the global companies are investing a substantial amount of funds to increase the export from the low-cost area, which is further likely to increase the HELLP syndrome diagnostic products in the domestic region during the forecast period.
The HELLP syndrome market is highly competitive, owing to the presence of big healthcare brands. The key HELLP syndrome players which are contributing to the growth of the global market include Roche, PerkinElmer Inc., DRG Instruments GmBH, DiabetOmics, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., Sera Prognostics, Inc., Shuwen Biotech Co. Ltd., Metabolomic Diagnostics Ltd., among others. The major players are adopting new product launch and expansion strategies for global growth in the HELLP syndrome market.
Overview: Siemens Healthineers AG (formerly Siemens Healthcare, Siemens Medical Solutions, and Siemens Medical System) is a medical technology company headquartered in Germany. The company dedicated to providing various healthcare products, particularly medical diagnostics solutions, healthcare equipment, and related services. Additionally, the company offers a broad range of products for several clinical specialties and diseases, such as oncology, cardiology, neurology, surgery, allergy & anemia, autoimmune disorders, women's health, bone metabolism and so on. Further, Siemens Healthineers is rapidly developing its product and service portfolio, with AI-driven applications and digital offerings that play a prominent role in shaping the future of healthcare. Moreover, it is present in more than 70 countries in the world, serving customized products and services to meet the needs of the local market, aiding from unsurpassed global expertise.
Product Portfolio: The company's portfolio for HELLP syndrome includes hemostasis assay ranges from standard PT and APTT testing to the breakthrough von Willebrand factor activity-testing technology in INNOVANCE VWF Ac Assay. Further, it recently launched a ready-to-use liquid INNOVANCE Heparin assay and new LOC assays, which further enhanced its portfolio by streamlining workflow and allowing labs to stay on the cutting-edge clinical innovations in hemostasis testing.
The global HELLP syndrome market report would provide access to an approx. 52 market data table, 51 figures and 270 pages.
LIST NOT EXHAUSTIVE